PNC Financial Services Group Inc. Sells 4,774 Shares of Genmab A/S (NASDAQ:GMAB)

PNC Financial Services Group Inc. trimmed its stake in shares of Genmab A/S (NASDAQ:GMAB) by 4.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,278 shares of the company’s stock after selling 4,774 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Genmab A/S were worth $2,274,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of the stock. Russell Investments Group Ltd. grew its holdings in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after acquiring an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of Genmab A/S by 123.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 3,240 shares of the company’s stock worth $81,000 after purchasing an additional 1,787 shares during the last quarter. Blue Trust Inc. increased its holdings in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares during the period. Headlands Technologies LLC lifted its holdings in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after buying an additional 4,853 shares during the period. Finally, Benjamin F. Edwards & Company Inc. grew its position in shares of Genmab A/S by 7.1% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after buying an additional 478 shares during the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of research analyst reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. BMO Capital Markets reissued an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research note on Friday, November 8th. Truist Financial cut their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a research report on Monday, September 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Stock Up 0.7 %

Shares of GMAB opened at $20.79 on Tuesday. The stock has a market cap of $13.76 billion, a P/E ratio of 20.18, a P/E/G ratio of 0.64 and a beta of 0.99. The business’s 50 day moving average price is $23.04 and its 200-day moving average price is $25.81. Genmab A/S has a 52 week low of $20.34 and a 52 week high of $32.88.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million during the quarter, compared to the consensus estimate of $838.20 million. During the same period last year, the firm posted $0.47 earnings per share. On average, equities analysts anticipate that Genmab A/S will post 1.28 EPS for the current year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.